Royal Bank of Canada
EPRX

Royal Bank of Canada’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Royal Bank of Canada’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Buy
311,435
+50,059
+19% +$345K ﹤0.01% 3292
2026
Q1 		$1.89M Buy
261,376
+65,099
+33% +$524K ﹤0.01% 3134
2025
Q4 		$1.48M Sell
196,277
-232,527
-54% -$1.43M ﹤0.01% 3350
2025
Q3 		$2.53M Buy
428,804
+220
+0.1% +$1.2K ﹤0.01% 3204
2025
Q2 		$2.47M Buy
428,584
+85,756
+25% +$329K ﹤0.01% 3128
2025
Q1 		$1.13M Buy
342,828
+59,683
+21% +$206K ﹤0.01% 3376
2024
Q4 		$898K Buy
283,145
+11,858
+4% +$35.1K ﹤0.01% 3632
2024
Q3 		$714K Buy
271,287
+5,543
+2% +$14.6K ﹤0.01% 3819
2024
Q2 		$686K Buy
+265,744
New +$739K ﹤0.01% 3764

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Royal Bank of Canada's EPRX Position: Q2 2026 in Review

Royal Bank of Canada increased its Eupraxia Pharmaceuticals (EPRX) stake by 19% in Q2 2026, buying an estimated $345K and bringing the position to 311,435 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3292.

Royal Bank of Canada first reported a position in EPRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.53M in Q3 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Royal Bank of Canada held 311,435 shares of Eupraxia Pharmaceuticals worth $2.06M as of Q2 2026.
  • Royal Bank of Canada bought 50,059 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $345K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #3292 holding.
  • Royal Bank of Canada first reported a position in Eupraxia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Royal Bank of Canada's Eupraxia Pharmaceuticals position peaked at $2.53M in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.